Fidelity Investments’s Monopar Therapeutics MNPR Stock Holding History
Bought
Maintained
Sold
Other funds holding MNPR
SVCM
SL
Fidelity Investments's MNPR Position: Q3 2026 in Review
Fidelity Investments increased its Monopar Therapeutics (MNPR) stake by 9.1% in Q3 2026, buying an estimated $5.15K and bringing the position to 578 shares worth $46K. The position accounts for ﹤0.01% of the portfolio, ranked #4375.
Fidelity Investments first reported a position in MNPR in Q2 2022 and has held it in 9 quarters since. The position peaked at $49.1K in Q2 2026. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.
- Fidelity Investments held 578 shares of Monopar Therapeutics worth $46K as of Q3 2026.
- Fidelity Investments bought 48 Monopar Therapeutics shares in Q3 2026, an estimated $5.15K.
- Monopar Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #4375 holding.
- Fidelity Investments first reported a position in Monopar Therapeutics in Q2 2022 and has held it in 9 quarters since.
- Fidelity Investments's Monopar Therapeutics position peaked at $49.1K in Q2 2026.
- 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.
Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.